Apyx Medical (NASDAQ:APYX) Issues Earnings Results

Apyx Medical (NASDAQ:APYX) posted its earnings results on Thursday. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05, FiscalAI reports. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The business had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported third-quarter revenue of $14 million, up 9% year over year, led by 17% growth in Surgical Aesthetics. OEM revenue fell 41.5%, partially offsetting that growth.
• The company said AYON’s power-liposuction rollout is underway and surgeon feedback has been positive; management sees additional growth potential as it pursues regulatory approvals in international markets, though it gave no approval timelines.
• Apyx reported positive EBITDA on a trailing 12-month basis and $0.4 million in adjusted EBITDA for the quarter, versus a loss a year earlier. Operating cash use also declined year over year, and cash stood at $25.8 million at quarter-end.
• Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target to $41 million–$42.5 million from less than $45 million. It now expects full-year gross margins of 63%–64%.

Apyx Medical Stock Up 17.6%

Shares of APYX stock traded up $0.46 during mid-day trading on Thursday, hitting $3.04. 994,957 shares of the stock traded hands, compared to its average volume of 122,382. Apyx Medical has a 52-week low of $2.25 and a 52-week high of $5.08. The stock has a market cap of $128.27 million, a P/E ratio of -15.22 and a beta of 1.47. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53. The stock’s fifty day moving average is $2.74 and its two-hundred day moving average is $3.59.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on APYX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, September 21st. HC Wainwright initiated coverage on shares of Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Maxim Group assumed coverage on Apyx Medical in a report on Tuesday, September 29th. They set a “buy” rating and a $6.00 target price for the company. Finally, Zacks Research raised Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Apyx Medical News Roundup

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Apyx Medical Company Profile

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.